Results
1 -
10 of
10Giannetti Anthony M., Zheng Xiaozhang, Skelton Nicholas J., Wang Weiru, Bravo Brandon J., Bair Kenneth W., Baumeister Timm, Cheng Eric, Crocker Lisa, Feng Yezhen, Gunzner-Toste Janet, Ho Yen-Ching, Hua Rongbao, Liederer Bianca M., Liu Yongbo, Ma Xiaolei, O’Brien Thomas, Oeh Jason, Sampath Deepak, Shen Youming, Wang Chengcheng, Wang Leslie, Wu Hongxing, Xiao Yang, Yuen Po-wai, Zak Mark, Zhao Guiling, Zhao Qiang, Dragovich Peter S..
Fragment-Based Identification of Amides Derived fromtrans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT), Journal of Medicinal Chemistry, 2014 Theeramunkong S., Galli U., Grolla A. A., Caldarelli A., Travelli C., Massarotti A., Troiani M. P., Alisi M. A., Orsomando G., Genazzani A. A., Tron G. C..
Identification of a novel NAMPT inhibitor by combinatorial click chemistry and chemical refinement, Med. Chem. Commun., 2015 Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA, Cancer & Metabolism Understanding Cancer Metabolism Through Global Metabolomics, Genetics Meets Metabolomics NF-?? B as a Molecular Target in the Therapy of Pancreatic Carcinoma, Pancreatic Cancer Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines, Cardiovascular Toxicology Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation, Cellular Oncology Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug, BMC Research Notes Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase, BMC Cancer